ING Groep NV vs uniQure N.V. Ordinary Shares — how do they compare? ING Groep NV trades at $33.34 (market cap $94.92B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: ING Groep NV is far larger — about 65.5× uniQure N.V. Ordinary Shares's market cap, and ING Groep NV pays a 3.93% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ING | QURE | |
|---|---|---|
Market Cap | $94.92B | $1.45B |
Volume | 2,055,666 | 3,323,243 |
Sector | Financials | Health |
52-Week High | $37.27 | $70.59 |
52-Week Low | $23.66 | $9.03 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $237.77B | $707.46M |
Dividend Yield | 3.93% | — |
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.63, up 0.72% today, with a bearish technical signal but strong fundamentals including a 28.34% net income margin and consistent earnings beats. Recent news highlights management's raised ROE target above 16% for 2027, driven by revenue growth and AI initiatives. Cash flow trends show volatile net outflows, with 2025 net cash flow at -$14.92 billion.
The outlook is mixed: analyst consensus is bullish with 65% buy ratings, but technical indicators and cash flow volatility pose risks. Upside potential hinges on execution of growth strategies and cost discipline, while regulatory scrutiny and macroeconomic pressures remain key watchpoints for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →